Efficacy of memantine treatment for the prevention and restration to cognitive dysfunction in patients receiving radiochemotherapy combined with hyperbaric oxygenation

Efficacy of memantine treatment for the prevention and restration to cognitive dysfunction in patients receiving radiochemotherapy combined with hyperbaric oxygenation - Efficancy of memantine treatment in cognitive dysfunction of patients with malignant gliomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018130

Enrollment

Registered

2015-07-31

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with malignant glioma

Interventions

Patients have 5mg of memantine during radiotherapy. Patients have 20mg of memantine during radiotherapy. They begin to have 5mg of memantine in the first week.Then a dose is escalating 5mg per week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient with malignant glioma (grade 3-4) receiving radiochemotherapy combined with hyperbaric oxygenation

Exclusion criteria

Exclusion criteria: 1.Patient with hypersensitivity for memantine 2.Patients with renal dysfunction 3.Patients with having factor ascend urinary pH 4.Patients with hepatic insufficiency 5.Patients with pregnancy 6.Patients who need the continuous medication having drug interact with memantine 7.Patients who were judged by doctors as not being appropriate subjects

Design outcomes

Primary

Measure	Time frame
Pattern separation ability Executive function, processing speed, attention, visuo-spatial function	—

Secondary

Measure	Time frame
Overall survival Progression free survival	—

Countries

Japan

Contacts

Public ContactYoshiki Oshiro

Graduate school of medicine, Department of neurosurgery

h149440@med.u-ryukyu.ac.jp098-895-1171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026